AXDX Profile
Accelerate Diagnostics, Inc. is a prominent in vitro diagnostics company specializing in advanced solutions for the rapid diagnosis of serious infections. Operating across the United States, Europe, and the Middle East, the company focuses on addressing critical needs in the identification and management of infectious diseases through innovative diagnostic technologies.
Central to Accelerate Diagnostics’ offerings is the Accelerate Pheno system, a cutting-edge in vitro diagnostic platform designed to identify pathogens and perform antibiotic susceptibility testing. This system targets a broad range of pathogens, including both gram-positive and gram-negative organisms, which are associated with serious or healthcare-associated infections. By providing rapid and accurate results, the Accelerate Pheno system helps clinicians make informed decisions about appropriate antimicrobial therapies, thereby improving patient outcomes and combating antibiotic resistance.
The company also offers the Accelerate PhenoTest, a specialized test kit for use with the Accelerate Pheno system. This kit provides critical diagnostic information for patients suspected of bacteremia or fungemiaâ€serious conditions that pose significant risks of morbidity and mortality. The PhenoTest enables timely identification and susceptibility profiling of pathogens, which is essential for effective treatment and management of these life-threatening infections.
Originally known as Accelr8 Technology Corporation, the company rebranded to Accelerate Diagnostics, Inc. in December 2012. Founded in 1982 and headquartered in Tucson, Arizona, Accelerate Diagnostics continues to lead the field of diagnostic innovation with a commitment to enhancing the speed and accuracy of infection detection. The company’s advanced diagnostic solutions support healthcare providers in delivering precise and timely care, ultimately contributing to improved patient outcomes and the effective management of infectious diseases.
|
